# Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance

> **NCT04062890** · PHASE2 · WITHDRAWN · sponsor: **University of Arizona**

## Conditions studied

- Hyperinsulinism
- Insulin Resistance
- Insulin Sensitivity
- Glucose Intolerance
- Hypertension

## Interventions

- **DRUG:** Vigabatrin Pill
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04062890
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2030-04-15
- **Primary completion:** 2030-12-30
- **Final completion:** 2030-12-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was never opened at University of Arizona.
- **Last updated:** 2025-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04062890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04062890, "Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04062890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*